US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.

On Wednesday, Omeros Corporation (OMER.US) surged by 150%, reaching a new high for the year at $10.27. In terms of news, Novo Nordisk A/S Sponsored ADR Class B announced today that they have reached a final agreement with the company regarding the candidate drug zaltenibart (OMS906). This drug is currently undergoing clinical development for rare blood and kidney diseases. According to the terms of the agreement, Novo Nordisk A/S Sponsored ADR Class B will receive exclusive rights to develop and commercialize zaltenibart globally. The company is eligible to receive an upfront payment of $340 million and milestone payments totaling up to $2.1 billion, including potential development and commercialization milestones. Additionally, there are tiered royalty fees based on net sales.